| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1d3a63854c7a1afe23086eebce835f46 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S436-813 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-43504
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
1996-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d03db77eacd02c6636fceb7163117832
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a34ef24d02e58389195a6b79375de001
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb0a44f75fc58424678d60fa9e5425d0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_581ca308d7350fc3a786b7cbf85ccd8b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce018896320e481d1dae76506e9cd096 |
| publicationDate |
1998-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0844883-A1 |
| titleOfInvention |
Use of conotoxin peptides u002 and mii for treating or detecting small-cell lung carcinoma |
| abstract |
The present invention is directed to use of relatively short peptides, spefically the α-conotoxin peptides MII and U002, for treating patients with small-cell lung carcinoma (SCLC) or for detecting the presence of SCLC tumors. It has been discovered that while MII and U002 bind to neuronal nicotinic receptors as do other α-conotoxin peptides, they have a significantly lower affinity for neuromuscular receptors. Patients having SCLC are treated in accordance with the present invention by administering, preferably intravenously or intramuscularly, a pharmaceutical composition containing the α-conotoxin peptide as the active ingredient. The presence or location of SCLC tumors are detected in accordance with the present invention by injecting a subject with MII or U002 labeled with a marker capable of detection and subsequently detecting the binding of the labeled MII or U002 to determine the presence or location of SCLC tumors. |
| priorityDate |
1995-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |